FDA rejects oral treprostinil diolamine for pulmonary arterial hypertension
Source: Reuters Health News Area: News Reuters Health News has reported that the US Food and Drug Administration (FDA) has denied approval of oral treprostinil diolamine for the treatment of pulmonary arterial hypertension. The drug was first rejected by the FDA in October 2012 after it had failed to show statistically significant results in patients taking the six-minute walk test during clinical studies. The report does not provide information on the reasons for the rejection. [Editor's note: Treprostinil is not licensed in the UK.]
CONCLUSIONS: Pregnant women are overweight/obese, with a mean age of 30.9 years and are socially vulnerable. Pregnant women with chronic hypertension are older and have a higher number of abortions. PMID: 32491150 [PubMed - as supplied by publisher]
Widely used drugs to control high blood pressure may help protect against severe COVID-19, a new study found, allaying concerns that they could make the illness caused by the coronavirus worse.
Atrial fibrillation is the most common sustained cardiac arrhythmia in the general population. In western countries with aging populations, atrial fibrillation poses a significant health concern, as it is associated with a high risk of thromboembolism, stroke, congestive heart failure, and myocardial infarction. Thrombi are generated in the left atrial appendage, and subsequent embolism into the cerebral circulation is a major cause of ischemic stroke. Therefore, patients have a lifetime risk of stroke, and those at high risk, defined as a CHA2DS2-VASc2 (congestive heart failure, hypertension, age>75 years, diabetes mel...
Baseline characteristics predicting clinical outcomes and serious adverse events in middle-aged hypertensive women: a sub-analysis of the SPRINT in women aged
Authors: Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, Alarcon-De-la-Vega G, Alvarado-Arnez LE, Balderrama-Saavedra MA, Bonilla-Aldana DK, Rodriguez-Morales AJ Abstract The present study is aimed to assess the risk factors for mortality in the first 107 rRT-PCR confirmed cases of SARS-CoV-2 infections in Bolivia. For this observational, retrospective and cross-sectional study, the epidemiological data records were collected from the Hospitals and the Ministry of Health of Bolivia, obtaining the clinical and epidemiological data of the COVID-19 cases that were laboratory-diagnosed during March 2-29,...
ConclusionsFrom the results of the CEPH model dogs, autonomic dysfunction was shown to occur in PH dogs. In addition, the administration of 1 mg/kg of sildenafil to CEPH model dogs may improve autonomic dysfunction.
AbstractFor most chronic medical conditions, multiple medications are available and prescribers often have limited evidence about which therapy is likely to be the most effective and safe for an individual patient. As many patients are exposed every day to medicines that may be less effective than available alternatives, this is of public health importance. Cluster randomised trials of prescribing policy offer an opportunity to rapidly obtain evidence of comparative effectiveness and safety. These trials can pose a low risk to patients and cause minimal disruption to usual care. Despite the potential scientific value of th...
This report provides 2017-2018 U.S. hypertension prevalence estimates using the 2017 American College of Cardiology and American Heart Association definition of hypertension (3) and new guidelines, which redefine hypertension by lowering the previous threshold levels of 140/90 mmHg to 130/80 mmHg (4). This change categorizes a greater percentage of people as having hypertension. PMID: 32487290 [PubMed - in process]
HIGH blood pressure has often been described as an insidious medical condition as the symptoms can be difficult to recognise without using a blood pressure monitor. Many people do not experience symptoms until their blood pressure is dangerously high and this can sometimes be too late. Feeling this sensation in your head could indicate high blood pressure.
Conclusion ACE I/D polymorphism may protect against the development of PE. PMID: 32484368 [PubMed - as supplied by publisher]